TY  -  
T1  - Real-world efficacy of bezlotoxumab for prevention of recurrent Clostridium difficile infection : a retrospective study of 46 patients in five university hospitals in Finland 
SN  -  /  
UR  - http://hdl.handle.net/10138/306807 
T3  -  
A1  - Oksi, Jarmo; Aalto, A.; Saila, P.; Partanen, T.; Anttila, Veli-Jukka A; Mattila, E. 
A2  -  
PB  -  
Y1  - 2019 
LA  - eng 
AB  - Reports on real-world experience on efficacy of bezlotoxumab (BEZ) has been lacking thus far. We retrospectively studied the efficacy and safety of BEZ in preventing the recurrence of Clostridium difficile infection (CDI) in five university hospitals in Finland. Seventy-three percent of our 46 patients remained free of recurrence in the following 3 months and the performance remained as 71% effective also among immunocompromised patients. In severe CDI, BEZ prevented recurrence in 63% of cases. ... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - Clostridium difficile infection; Recurrence; Bezlotoxumab; RISK-FACTORS; VANCOMYCIN; METRONIDAZOLE; FIDAXOMICIN; OUTCOMES; THERAPY; DISEASE; 3121 General medicine, internal medicine and other clinical medicine; 1183 Plant biology, microbiology, virology 
N1  -   
PP  -  
ER  -